Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Evaluation of Aftobetin-HCl and Fluorescence Detection as Measured by Sapphire II to Determine the Number and Timing of Administrations in Subjects With Normal Cognition, Mild Cognitive Impairment, and Mild Alzheimer's Disease

NCT02928211 is registered in ClinicalTrials.gov with Cognoptix, Inc. as lead sponsor.

NCT NCT02928211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02928211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Evaluation of Aftobetin-HCl and Fluorescence Detection as Measured by Sapphire II to Determine the Number and Timing of Administrations in Subjects With Normal Cognition, Mild Cognitive Impairment, and Mild Alzheimer's Disease
Lead sponsor
Cognoptix, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
July 31, 2016
Completion date
January 31, 2019
Enrollment
105 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, mild cognitive impairment